We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Rheumatology

Journal Scan / Review · January 24, 2022

Clinical Overview of Systemic Sclerosis–Associated Interstitial Lung Disease

Arthritis & Rheumatology (Hoboken, N.J.)


Additional Info

Arthritis & Rheumatology (Hoboken, N.J.)
Systemic Sclerosis-Associated Interstitial Lung Disease: How to Incorporate Two Food and Drug Administration-Approved Therapies in Clinical Practice
Arthritis Rheumatol 2022 Jan 01;74(1)13-27, D Khanna, A Lescoat, D Roofeh, EJ Bernstein, EA Kazerooni, MD Roth, F Martinez, KR Flaherty, CP Denton

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading